Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL221679 | 1.00 | TSHR (0.43) | TSHRTP53LMNAF2ALDH1A1 | |
| SCHEMBL27362899 | 1.00 | TSHR (0.43) | TSHRTP53LMNAF2ALDH1A1 | |
| SCHEMBL7686 | 1.00 | TSHR (0.43) | TSHRTP53LMNAF2ALDH1A1 | |
| SCHEMBL223031 | 1.00 | TSHR (0.43) | TSHRTP53LMNAF2ALDH1A1 | |
| SCHEMBL1483657 | 1.00 | TSHR (0.43) | TSHRTP53LMNAF2ALDH1A1 | |
| SCHEMBL3946464 | 0.98 | TSHR (0.42) | TSHRTP53LMNAF2ALDH1A1 | |
| Water SCHEMBL1818831 | 0.98 | TSHR (0.42) | TSHRTP53LMNAF2ALDH1A1 | |
| Water SCHEMBL789812 | 0.98 | TSHR (0.42) | TSHRTP53LMNAF2ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL11444698 | 0.98 | TSHR (0.42) | TSHRTP53LMNAF2ALDH1A1 | |
| SCHEMBL11542849 | 0.98 | TSHR (0.42) | TSHRTP53LMNAF2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103965198-A | Ticagrelor intermediate, preparation method of intermediate and method for preparing ticagrelor by using intermediate | HAO CONGMEI | 2014-08-06 | — | — | CN | claimed |
| CN-103965059-A | Method for preparation of (1R,2S)-2-(3,4-difluorophenyl)cyclopropylamine | SHANGHAI SYNCORES TECHNOLOGIES INC | 2014-08-06 | — | — | CN | claimed |
| CN-103755701-A | Preparation method of pyrazino amine salt and corresponding pyrazino amine with optical activity | UNIV SHANDONG WEIHAI | 2014-04-30 | — | — | CN | claimed |
| CN-103724346-A | Sinensis amine salt with optical activity and corresponding preparation method of sinensis amine | UNIV SHANDONG WEIHAI | 2014-04-16 | — | — | CN | claimed |
| CN-103626745-A | Preparation method for ticagrelor intermediate | QINGDAO HUANGHAI PHARMACEUTICAL CO LTD | 2014-03-12 | — | — | CN | claimed |
| CN-118255785-A | Chiral AIEgens of cinchona alkaloid amide skeleton, preparation method and application | 宝鸡文理学院 | 2024-06-28 | — | — | CN | disclosed |
| US-11999744-B2 | Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making | BLUEPRINT MEDICINES CORPORATION (US) | 2024-06-04 | — | — | US | disclosed |
| WO-2024017170-A1 | S-(-)-NICOTINE(-)-DIBENZOYL-L-TARTRATE CRYSTAL FORM, PREPARATION METHOD AND USE | 北京世桥生物制药有限公司 | 2024-01-25 | — | — | WO | disclosed |
| CN-108440349-B | Preparation method of chiral optical pure p-toluenesulfinamide | 上海李氏化学科技有限公司 | 2020-10-20 | — | — | CN | disclosed |
| CN-108558714-B | Preparation method of chiral optical pure p-toluenesulfinamide | 上海李氏化学科技有限公司 | 2020-10-16 | — | — | CN | disclosed |
| CN-108409615-B | Method for synthesizing enantiopure tert-butyl sulfenamide | 大连双硼医药化工有限公司 | 2020-09-11 | — | — | CN | disclosed |
| CN-108467353-B | Preparation method of enantiopure tert-butyl sulfinamide | 大连双硼医药化工有限公司 | 2020-09-11 | — | — | CN | disclosed |
| WO-2004050615-A2 | METHOD OF INCREASING NEUTROPHIL PRODUCTION USING 2,3-BENZODIAZEPINES | VELA PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050040-A2 | PHARMACEUTICAL COMPOSITION OF 1-(3,4-DIMETHOXYPHENYL)-4-METHYL-5-ETHYL-7-METHOXY-8-HYDROXY-5H-2,3-BENZODIAZEPINE AND USES THEREOF | VELA PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20040106602-A1 | Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2004-06-03 | — | — | US | disclosed |
| US-20040106601-A1 | Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2004-06-03 | — | — | US | disclosed |
| US-6683072-B1 | EFFECTIVE LONG TERM ALLEVIATION | VELA PHARMACEUTICALS, INC. | 2004-01-27 | — | — | US | disclosed |
| CN-1430610-A | Substituted 1-aminoalkyllactam compounds and their use as muscarinic receptor antagonists | HOFFMANN LA ROCHE (CH) | 2003-07-16 | — | — | CN | disclosed |
| CN-1069314-C | 2-oxoindoline derivatives | TANABE SEIYAKU CO (JP) | 2001-08-08 | — | — | CN | disclosed |
| CN-1136310-A | 2-oxoindoline derivatives | TANABE SEIYAKU CO (JP) | 1996-11-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106602-A1 | Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines | LTB4R2, LTB4R, PTGER4 | TSHR 529/4885TP53 4854/4885LMNA 1827/4885 |
| US-11999744-B2 | Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making | PDGFRA, KIT, PDGFRB | TSHR 2783/4885TP53 6/4885LMNA 639/4885 |
| US-20040106601-A1 | Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines | OPRL1, OPRD1, GABRR1 | TSHR 416/4885TP53 4729/4885LMNA 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.